



3.5.5 Cancer Molecular Pathology and Therapeutic Targets Group

Publications: 23

Impact Factor: 133.⁸⁵⁴

Q1: 15



Research Activity

Publications

- Alcala S, Mayoral-Varo V, Ruiz-Canas L, López-Gil JC, Heeschen C, Martín-Pérez J, Sainz B. Targeting SRC kinase signaling in pancreatic cancer stem cells. *Int J Mol Sci.* 2020; 21(20): 7437. Article. IF: 5.923; Q1
- Casas-Arozamena C, Díaz E, Moiola CP, Alonso-Alconada L, Ferreiros A, Ábalo A, Gil CL, Oltra SS, de Santiago J, Cabrera S, Sampayo V, Bouso M, Arias E, Cueva J, Colas E, Vilar A, Gil-Moreno A, Abal M, Moreno-Bueno G, Muñelo-Romay L. Genomic profiling of uterine aspirates and cfDNA as an integrative liquid biopsy strategy in endometrial cancer. *J Clin Med.* 2020; 9(2): 585. Article. IF: 4.241; Q1
- Costales-Carrera A, Fernández-Barral A, Bustamante-Madrid P, Domínguez O, Guerra-Pastrán L, Cantero R, del Peso L, Burgos A, Barbachano A, Muñoz A. Comparative study of organoids from patient-derived normal and tumor colon and rectal tissue. *Cancers.* 2020; 12(8): 2302. Article. IF: 6.639; Q1
- COVIDSurg Collaborative [Sánchez-Méndez JJ]. Delaying surgery for patients with a previous SARS-CoV-2 infection. *Br J Surg.* 2020; 107(12): E601-2. Letter. IF: 6.939; D1
- del Arco CD, Muñoz LE, Manchado RB, García AP, Medina LO, Roldán EM, Fernández GS, de las Heras SGG, Acenero MJF. Prognostic role of aryl hydrocarbon receptor interacting protein [AIP] immunohistochemical expression in patients with resected gastric carcinomas. *Pathol Oncol Res.* 2020; 26(4): 2641-50. Article. IF: 3.201; Q2
- Escoll M, Lastra D, Pajares M, Robledinos-Antán N, Rojo AI, Fernández-Ginés R, Mendiola M, Martínez-Marín V, Esteban I, López-Larrubia P, Gargini R, Cuadrado A. Transcription factor NRF2 uses the Hippo pathway effector TAZ to induce tumorigenesis in glioblastomas. *Redox Biol.* 2020; 30: 101425. Article. IF: 11.799; D1
- Fernández-Barral A, Costales-Carrer A, Buira SP, Jung P, Ferrer-Mayorga G, Larriba MJ, Bustamante-Madrid P, Domínguez O, Real FX, Guerra-Pastrán L, Lafarga M, García-Olmo D, Cantero R, del Peso L, Batllé E, Rojo F, Muñoz A, Barbachano A. Vitamin D differentially regulates colon stem cells in patient-derived normal and tumor organoids. *FEBS J.* 2020; 287(1): 53-72. Article. IF: 5.542; Q1
- Garranzo-Asensio M, San Segundo-Acosta P, Poves C, Fernández-Acenero MJ, Martínez-Useros J, Montero-Calle A, Solís-Fernández G, Sánchez-Martínez M, Rodríguez N, Cerón MA, Fernández-Díez S, Domínguez G, de Los Ríos V, Peláez-García A, Guzmán-Aránguez A, Barderas R. Identification of tumor-associated antigens with diagnostic ability of colorectal cancer by in-depth immunomic and seroproteomic analysis. *J Proteomics.* 2020; 214: 103635. Article. IF: 4.044; Q2
- Goebel EA, Hernández Bonilla S, Dong F, Dickson BC, Hoang LN, Hardisson D, Lacambra MD, Lu FI, Fletcher CDM, Crum CP, Antonescu CR, Nucci



3.5 Cancer and Human Molecular Genetics Area

MR, Kolin DL. Uterine tumor resembling ovarian sex cord tumor (UTROSCT) a morphologic and molecular study of 26 cases confirms recurrent NCOA1-3 rearrangement. *Am J Surg Pathol*. 2020; 44(1): 30-42. Article. IF: 6.394; D1

- Heredia-Soto V, López-Guerrero J A, Redondo A, Mendiola M. The hallmarks of ovarian cancer: Focus on angiogenesis and micro-environment and new models for their characterisation. *EJC Suppl*. 2020; 15: 49-55. Article. IF: 9.386; D1
- Heredia-Soto V, Redondo A, Kreilinger JJP, Martínez-Marín V, Berjón A, Mendiola M. 3D culture modelling: An emerging approach for translational cancer research in sarcomas. *Curr Med Chem*. 2020; 27(29): 4778-88. Review. IF: 4.53; Q2
- Leskela S, Romero I, Cristóbal E, Pérez-Mies B, Rosa-Rosa JM, Gutiérrez-Pecharromán A, Santón A, González BO, López-Reig R, Hardisson D, Vera-Sempere F, Illueca C, Vieites B, López-Guerrero JA, Palacios J, Poveda A. The frequency and prognostic significance of the histologic type in early-stage ovarian carcinoma a reclassification study by the spanish group for ovarian cancer research (GEICO). *Am J Surg Pathol*. 2020; 44(2): 149-61. Article. IF: 6.394; D1
- López-Janeiro A, Padilla-Ansala C, de Andrea CE, Hardisson D, Melero I. Prognostic value of macrophage polarization markers in epithelial neoplasms and melanoma. A systematic review and meta-analysis. *Mod Pathol*. 2020; 33(8): 1458-65. Review. IF: 7.842; D1
- Martí C, Sánchez-Méndez JI. Neoadjuvant endocrine therapy for luminal breast cancer treatment: a first-choice alternative in times of crisis such as the COVID-19 pandemic. *eCancerMedicalScience*. 2020; 14: 1027. Article. Not Indexed
- Mayoral-Varo V, Calcabrini A, Sánchez-Bailón MP, Martínez-Costa OH, González-Páramos C, Ciordia S, Hardisson D, Aragón JJ, Fernández-Moreno MA, Martín-Pérez J. c-Src functionality controls self-renewal and glucose metabolism in MCF7 breast cancer stem cells. *PLoS One*. 2020; 15(7): e0235850. Article. IF: 3.24; Q2
- Nemejcova K, Kocian R, Kohler K, Jarkovsky J, Klat J, Berjón A, Pilka R, Sehna B, Gil-Ibáñez B, Lupo E, Petiz A, Sánchez OA, Kascak P, Martínelli

- F, Buda A, Presl J, Barahona M, van Lonkhuijzen L, Szatkowski W, Minar L, Pakiz M, Havelka P, Zorrero C, Misiek M, Snyman LC, Wydra D, Vergote I, Vinnytska A, Redecha M, Michal M, Tingulstad S, Kipp B, Szewczyk G, Toth R, García FJD, Martín PJC, Poka R, Tamussino K, Luyckx M, Fastrez M, Staringer JC, Germanova A, Plaikner A, Bajsova S, Dunder P, Mallmann-Gottschalk N, Cibula D. Central pathology review in sENTIX, a prospective observational international study on sentinel lymph node biopsy in patients with early-stage cervical cancer (ENGOT-CX2). *Cancers*. 2020; 12(5): 1115. Article. IF: 6.639; Q1
- Ordulu Z, Chai HY, Peng G, McDonald AG, de Nicolis M, García-Fernández E, Hardisson D, Prat J, Li PN, Hui P, Olival E, Buza N. Molecular and clinicopathologic characterization of intravenous leiomyomatosis. *Mod Pathol*. 2020; 33(9): 1844-60. Article. IF: 7.842; D1
- Pinero-Madrón A, Ripoll-Orts F, Sánchez-Méndez JI, Chaves-Benito A, Gómez-de la Barcena MR, Calatrava-Fons A, Menjón-Beltrán S, Peg-Camara V. External validation of a prognostic model based on total tumor load of sentinel lymph node for early breast cancer patients. *Breast Cancer Res Treat*. 2020; 181(2): 339-45. Article. IF: 4.872; Q2
- Povedano E, Montiel VRV, Gamella M, Pedrero M, Borderas R, Peláez-García A, Mendiola M, Hardisson D, Feliú J, Yáñez-Sedeno P, Campuzano S, Pingarrón JM. Amperometric bioplatfroms to detect regional DNA methylation with single-base sensitivity. *Anal Chem*. 2020; 92(7): 5604-12. Article. IF: 6.986; D1
- Schaumberg AJ, Juárez-Nicanor WC, Choudhury SJ, Pastríán LG, Pritt BS, Pozuelo MP, Sánchez RS, Ho K, Zahra N, Sener BD, Yip S, Xu B, Annavarapu SR, Morini A, Jones KA, Rosado-Orozco K, Mukhopadhyay S, Miguel C, Yang HY, Rosen Y, Ali RH, Folaranmi OO, Gardner JM, Rusu C, Staryman C, Gross J, Suleiman DE, Sirintrapun SJ, Aly M, Fuchs TJ. Interpretable multimodal deep learning for real-time pan-tissue pan-disease pathology search on social media. *Mod Pathol*. 2020; 33(11): 2169-85. Article. IF: 7.842; D1
- Trilla-Fuertes L, Ghanem I, Gámez-Pozo A, Maurel J, G-Pastríán L, Mendiola M, Pena C, López-Vacas R, Prado-Vázquez G, López-Camacho E, Zapater-Moros A, Heredia V, Cuatrecasas M, García-Alfonso P, Capdevila J, Conill C, García-Carbonero R, Ramos-Ruiz R, Fortes C, Llorens C, Nanni P, Vara JAF, Feliú J. Genetic profile and functional proteomics of anal squamous cell carcinoma: Proposal for a molecular classification. *Mol Cell Proteomics*. 2020; 19(4): 690-700. Article. IF: 5.911; Q1
- Trilla-Fuertes L, Ghanem I, Maurel J, G-Pastríán L, Mendiola M, Pena C, López-Vacas R, Prado-Vázquez G, López-Camacho E, Zapater-Moros A, Heredia V, Cuatrecasas M, García-Alfonso P, Capdevila J, Conill C, García-Carbonero R, Heath KE, Ramos-Ruiz R, Llorens C, Campos-Barros A, Gámez-Pozo A, Feliú J, Vara JAF. Comprehensive characterization of the mutational landscape in localized anal squamous cell carcinoma. *Transl Oncol*. 2020; 13(7): 100778. Article. IF: 4.243; Q2
- Vinal D, Martínez D, García-Cuesta JA, Gutiérrez-Sainz L, Martínez-Recio S, Villamayor J, Martínez-Marín V, Gallego A, Ortiz-Cruz E, Mendiola M, Pozo-Kreilinger JJ, Berjón A, Belinchón B, Bernabeu D, Espinosa E, Feliú J, Redondo A. Prognostic value of neutrophil-to-lymphocyte ratio and other inflammatory markers in patients with high-risk soft tissue sarcomas. *Clin Transl Oncol*. 2020; 22(10): 1849-56. Article. IF: 3.405; Q3

- E, Zapater-Moros A, Heredia V, Cuatrecasas M, García-Alfonso P, Capdevila J, Conill C, García-Carbonero R, Ramos-Ruiz R, Fortes C, Llorens C, Nanni P, Vara JAF, Feliú J. Genetic profile and functional proteomics of anal squamous cell carcinoma: Proposal for a molecular classification. *Mol Cell Proteomics*. 2020; 19(4): 690-700. Article. IF: 5.911; Q1
- Trilla-Fuertes L, Ghanem I, Maurel J, G-Pastríán L, Mendiola M, Pena C, López-Vacas R, Prado-Vázquez G, López-Camacho E, Zapater-Moros A, Heredia V, Cuatrecasas M, García-Alfonso P, Capdevila J, Conill C, García-Carbonero R, Heath KE, Ramos-Ruiz R, Llorens C, Campos-Barros A, Gámez-Pozo A, Feliú J, Vara JAF. Comprehensive characterization of the mutational landscape in localized anal squamous cell carcinoma. *Transl Oncol*. 2020; 13(7): 100778. Article. IF: 4.243; Q2
- Vinal D, Martínez D, García-Cuesta JA, Gutiérrez-Sainz L, Martínez-Recio S, Villamayor J, Martínez-Marín V, Gallego A, Ortiz-Cruz E, Mendiola M, Pozo-Kreilinger JJ, Berjón A, Belinchón B, Bernabeu D, Espinosa E, Feliú J, Redondo A. Prognostic value of neutrophil-to-lymphocyte ratio and other inflammatory markers in patients with high-risk soft tissue sarcomas. *Clin Transl Oncol*. 2020; 22(10): 1849-56. Article. IF: 3.405; Q3

Research projects

Guerra Pastríán L. Desarrollo de tareas de revisión patológica nacional del ensayo clínico Paediatric Hepatic International Tumour Trial (PHITT). Fundación para la Investigación Biomédica de Córdoba Fibico. 2019-Ongoing.

Managment centre: FIBHULP

Hardisson Hernández D. Aplicabilidad de la proteogenómica en la progresión del carcinoma endometrioide de endometrio diagnosticado en estadios iniciales (PI17/01723). ISCIII. 2018-2021.

Managment centre: FIBHULP

Hardisson Hernández D. Realización de las tareas necesarias para el desarrollo del ensayo clínico. A phase IB/IIA, randomized, double blind, placebo controlled, multicenter clinical trial to evaluate the safety, pharmacokinetics and efficacy of oral treatment with ost-122 in patients with moderate to severe ulcerative colitis. ct-ost-122-02. Oncostellae S.L. 2020-Ongoing.

Managment centre: FIBHULP

Hardisson Hernández D. Riesgo de recaída en pacientes con carcinoma de mama primario HER2 negativo y receptores estrogénicos positivos: estudio comparativo de dos perfiles de expresión génica (Mammaprint® y Endopredict®). Fundación Sociedad Española de Anatomía Patológica. 2019-Ongoing.

Managment centre: FIBHULP

Mendiola Sabio M, Hardisson Hernández D. Identificación de biomarcadores en cáncer de pulmón no microcítico. AstraZeneca Farmacéutica Spain S. A. 2020-Ongoing.

Managment centre: FIBHULP

Mendiola Sabio M. Exploration of 2 and 3d models of angiosarcoma and their farcological screening. Grupo Español de Investigación en Sarcomas. 2019-Ongoing.

Managment centre: FIBHULP

Mendiola Sabio M. Identificación de perfiles de expresión génica diferencial relacionados con la angiogénesis entre el carcinoma de ovario primario y sus metástasis. Orto-medimatec. 2012-Ongoing.

Managment centre: FIBHULP

Mendiola Sabio M. Papel de RANKL en el sarcoma de Ewing: un estudio in vitro para la confirmación de una nueva diana terapéutica. Grupo Español de Investigación en Sarcomas. 2012-Ongoing.

Managment centre: FIBHULP



3.5 Cancer and Human Molecular Genetics Area

Mendiola Sabio M. Realización de técnicas de detección de expresión proteica el IGTP. Construcción de matrices tisulares y tinciones con anticuerpos específicos. Fundación Institut D'investigació en Ciències de la Salut Germans Trias I Pujol. 2015-Ongoing.

Management centre: FIBHULP

Type: Estudios, phase No EPA.

HULP code: PI-3692 .

Sponsored's protocol code: GES-NEO-2019-001.

Sponsored by: Fundación Española de Senología .

Signed date: 27/01/2020

Clinical trials

Hardisson Hernández, D. Evaluación del método Osna para la detección rápida de metástasis en ganglios linfáticos en mujeres con cáncer endometrial.

Type: Estudios, phase No EPA.

HULP code: PI-4275A .

Sponsored's protocol code: CP-OSNA-EC-210.

Sponsored by: Sysmex Europe GmbH.

Signed date: 02/10/2020

Hardisson Hernández, D. Validación estudio Neovattl.

Patents and trademarks

Redondo Sánchez A, Hardisson Hernández D, Barriuso Feijoo J, Mendiola Sabio M, inventors; FIBHULP, assignee. Method to obtain useful data for the prediction of a patient's clinical response to an anticancer treatment. P200930400; 2009 July 01.

Redondo Sánchez A, Hardisson Hernández D, Barriuso Feijoo J, Mendiola Sabio M, inventors; FIBHULP, assignee. Method to obtain useful data for the prediction of a patient's pathological response to an anticancer treatment. P200930438; 2009 July 10.